Firms with manufacturing base in Brazil get priority in state-backed R&D programme
This article was originally published in Scrip
Pharma and medtech firms with manufacturing facilities in Brazil are being given priority in competitions for state co-funded R&D, under changes to the "production development partnership" (PDP) programme. This and other selection criteria and rules have been enacted by the health ministry through the bill Portaria 837, of 18 April 2012.
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.